Clinical Value of Molecular Genetic Analyzes in Gynecological Malignomas

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03194347

Acronym

MAGynMA

Enrollment

300

Registered

2017-06-21

Start date

2017-05-29

Completion date

2021-12-31

Last updated

2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecologic Cancer

Brief summary

The aim of the planned research project is to find out the clinical significance of molecular genetic analyzes in gynecological malignomas. In particular, it will be investigated how the knowledge of a molecular-genetic finding affects the therapeutic decision of the physician. Furthermore, genetic changes in the tumor tissue will be compared with the changes in CTCs, DTCs and cfDNA.

Interventions

DIAGNOSTIC_TESTmolecular genetic analyses

molecular genetic analyses

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with a solid tumor disease * The presence of a molecular genetic diagnosis of the tumor tissue from practice for human genetics * Age \> 18 years * informed consent

Exclusion criteria

* life expectancy \<12 months or worse general condition (Karnofsky \<70)

Design outcomes

Primary

Measure	Time frame	Description
Influence of molecular genetic findings to the therapy decision	3years	It will be analyzed if the physicians selection of a therapy is influenced by a present molecular genetic finding. Therapy recommondation based on molecular genetic analysis will be compared with the acutal therapy decision.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026